> Details

Rush, Hannah L.; Murphy, Laura; Morgans, Alicia K.; Clarke, Noel W.; Cook, Adrian D.; Attard, Gerhardt; Macnair, Archie; Dearnaley, David P.; Parker, Christopher C.; Russell, J. Martin; Gillessen, Silke; Matheson, David; Millman, Robin; Brawley, Christopher D.; Pugh, Cheryl; Tanguay, Jacob S.; Jones, Robert J.; Wagstaff, John; Rudman, Sarah; O'Sullivan, Joe M.; Gale, Joanna; Birtle, Alison; Protheroe, Andrew; Gray, Emma; [...]

Quality of Life in Men With Prostate Cancer Randomly Allocated to Receive Docetaxel or Abiraterone in the STAMPEDE Trial

Reference
management

Bookmarks

Remove from
bookmarks

Share this on Whatsapp

Close

Bookmarks



You can manage bookmarks using lists, please log in to your user account for this.
  • Media type: E-Article
  • Title: Quality of Life in Men With Prostate Cancer Randomly Allocated to Receive Docetaxel or Abiraterone in the STAMPEDE Trial
  • Contributor: Rush, Hannah L.; Murphy, Laura; Morgans, Alicia K.; Clarke, Noel W.; Cook, Adrian D.; Attard, Gerhardt; Macnair, Archie; Dearnaley, David P.; Parker, Christopher C.; Russell, J. Martin; Gillessen, Silke; Matheson, David; Millman, Robin; Brawley, Christopher D.; Pugh, Cheryl; Tanguay, Jacob S.; Jones, Robert J.; Wagstaff, John; Rudman, Sarah; O'Sullivan, Joe M.; Gale, Joanna; Birtle, Alison; Protheroe, Andrew; Gray, Emma; [...]
  • imprint: American Society of Clinical Oncology (ASCO), 2022
  • Published in: Journal of Clinical Oncology
  • Language: English
  • DOI: 10.1200/jco.21.00728
  • ISSN: 0732-183X; 1527-7755
  • Keywords: Cancer Research ; Oncology
  • Origination:
  • Footnote:
  • Description: <jats:sec><jats:title>PURPOSE</jats:title><jats:p> Docetaxel and abiraterone acetate plus prednisone or prednisolone (AAP) both improve survival when commenced alongside standard of care (SOC) androgen deprivation therapy in locally advanced or metastatic hormone-sensitive prostate cancer. Thus, patient-reported quality of life (QOL) data may guide treatment choices. </jats:p></jats:sec><jats:sec><jats:title>METHODS</jats:title><jats:p> A group of patients within the STAMPEDE trial were contemporaneously enrolled with the possibility of being randomly allocated to receive either docetaxel + SOC or AAP + SOC. A mixed-model assessed QOL in those who had completed at least one QLQ-C30 + PR25 questionnaire. The primary outcome measure was difference in global-QOL (QLQ-C30 Q29&amp;30) between patients allocated to docetaxel + SOC or AAP + SOC over the 2 years after random assignment, with a predefined criterion for clinically meaningful difference of &gt; 4.0 points. Secondary outcome measures included longitudinal comparison of functional domains, pain, and fatigue, plus global-QOL at defined timepoints. </jats:p></jats:sec><jats:sec><jats:title>RESULTS</jats:title><jats:p> Five hundred fifteen patients (173 docetaxel + SOC and 342 AAP + SOC) were included. Baseline characteristics, proportion of missing data, and mean baseline global-QOL scores (docetaxel + SOC 77.8 and AAP + SOC 78.0) were similar. Over the 2 years following random assignment, the mean modeled global-QOL score was +3.9 points (95% CI, +0.5 to +7.2; P = .022) higher in patients allocated to AAP + SOC. Global-QOL was higher for patients allocated to AAP + SOC over the first year (+5.7 points, 95% CI, +3.0 to +8.5; P &lt; .001), particularly at 12 (+7.0 points, 95% CI, +3.0 to +11.0; P = .001) and 24 weeks (+8.3 points, 95% CI, +4.0 to +12.6; P &lt; .001). </jats:p></jats:sec><jats:sec><jats:title>CONCLUSION</jats:title><jats:p> Patient-reported QOL was superior for patients allocated to receive AAP + SOC, compared with docetaxel + SOC over a 2-year period, narrowly missing the predefined value for clinical significance. Patients receiving AAP + SOC reported clinically meaningful higher global-QOL scores throughout the first year following random assignment. </jats:p></jats:sec>
  • Access State: Open Access